Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 10:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo first Clear all
Recruiting Not applicable Interventional

Non-Invasive Low Intensity Focused Ultrasound Stimulation for Drug-Resistant Epilepsy

NCT07680842
View directory record Official record
Conditions
Drug-Resistant Epilepsy, Epilepsy, Epilepsy (Treatment Refractory), Epilepsy Comorbidities, Epilepsy, Drug Resistant, Epilepsy, Generalized, Epilepsy, Focal
Interventions
Target optimization using LIFU, Serial LIFU stimulation
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 15, 2026, 10:48 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Residual Effects of Intoxication on Student Performance

NCT00183170
View directory record Official record
Conditions
Alcoholic Intoxication, Neurobehavioral Manifestations
Interventions
Alcohol, Placebo
Drug · Other
Lead sponsor
Boston University
Other
Eligibility
21 Years to 30 Years
Enrollment
239 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 15, 2026, 10:48 AM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

NCT03726879
View directory record Official record
Conditions
Breast Cancer
Interventions
Atezolizumab, Placebo, Doxorubicin, Cyclophosphamide, Paclitaxel, Trastuzumab, Pertuzumab, Trastuzumab Emtansine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Kansas City, Missouri • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 15, 2026, 10:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First Time in Human Study of Protexia

NCT00744146
View directory record Official record
Conditions
Intervention for Nerve Agent Exposure
Interventions
Protexia
Biological
Lead sponsor
PharmAthene, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2010 · Synced Sep 15, 2026, 10:48 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Use of Pycnogenol® to Alleviate Menopausal Symptoms Induced or Increased by Breast and Gynecological Cancer Treatments

NCT03704454
View directory record Official record
Conditions
Climacteric; Menorrhagia, Menopausal, Menopause
Interventions
50 mg PYC and then placebo, 100 mg PYC and then placebo, Placebo and then 50 mg PYC, Placebo and then 100 mg PYC
Dietary Supplement
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
3
States / cities
Gresham, Oregon • Portland, Oregon • Tualatin, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 15, 2026, 10:48 AM EDT
Completed Phase 3 Interventional Results available

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

NCT03374488
View directory record Official record
Conditions
UC (Urothelial Cancer)
Interventions
Pembrolizumab, Epacadostat, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
24
States / cities
Chandler, Arizona • Orange, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 15, 2026, 10:48 AM EDT
Terminated Phase 2 Interventional Results available

Neurosteroids in PTSD - Biomarkers to Therapeutics

NCT03491007
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
DHEA
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 15, 2026, 10:48 AM EDT
Completed Phase 4 Interventional Results available

Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD)

NCT01517711
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Tramadol, Placebo
Drug
Lead sponsor
INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium
Other
Eligibility
21 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Sep 15, 2026, 10:48 AM EDT
Withdrawn Phase 2 Interventional

A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders

NCT05974293
View directory record Official record
Conditions
NMO Spectrum Disorder, Spasticity, Muscle
Interventions
Nabiximols, Placebo
Drug
Lead sponsor
Michael, Levy M.D.,Ph.D.
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Sep 15, 2026, 10:48 AM EDT
Completed Not applicable Interventional Results available

Antidepressant Treatment Plus Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Older Adults

NCT00601965
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Escitalopram, Placebo, Cognitive behavioral therapy (CBT)
Drug · Behavioral
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
60 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
San Diego, California • St Louis, Missouri • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Sep 15, 2026, 10:48 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Omega-3D: Omega-3 for Diet-Driven Health Disparities

NCT07078344
View directory record Official record
Conditions
Heart Health Markers, Cardiovascular Diseases, Omega 3 Fatty Acids
Interventions
Omega-3 Fatty Acids and Safflower Oil Placebo, Safflower Oil Placebo and Omega-3 Fatty Acids
Dietary Supplement
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 64 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Tucson, Arizona • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 15, 2026, 10:48 AM EDT
Completed Phase 1 Interventional

A Dose Escalation Study of Intranasal Neuropeptide Y in Post Traumatic Stress Disorder (PTSD)

NCT01533519
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Neuropeptide Y
Drug
Lead sponsor
James Murrough
Other
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 15, 2026, 10:48 AM EDT
Terminated Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

NCT05660265
View directory record Official record
Conditions
Hematologic Diseases, Anaemia, Sickle Cell
Interventions
GSK4172239D, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Miami, Florida • Tamarac, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 15, 2026, 10:48 AM EDT
Completed Phase 2 Interventional

Pleconaril Enteroviral Sepsis Syndrome

NCT00031512
View directory record Official record
Conditions
Enterovirus Infection
Interventions
Placebo, Pleconaril
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
0 Days to 15 Days
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2024 · Synced Sep 15, 2026, 10:48 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)

NCT03608163
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness
Interventions
Naloxone, Diazoxide, Placebo (for Naloxone), Placebo (for Diazoxide)
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 15, 2026, 10:48 AM EDT
Withdrawn Phase 4 Interventional

Spironolactone to Improve Apnea and Cardiovascular Markers in Obstructive Sleep Apnea Patients

NCT04205136
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Sep 15, 2026, 10:48 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)

NCT02079909
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
T-817MA-H, T-817MA-L, Placebo
Drug
Lead sponsor
FUJIFILM Toyama Chemical Co., Ltd.
Industry
Eligibility
55 Years to 85 Years
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
50
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 15, 2026, 10:48 AM EDT
Terminated Phase 1 Interventional Results available

DOSE Trial of Opioid Sparing Effect

NCT03938857
View directory record Official record
Conditions
Dexmedetomidine, Mechanical Ventilation Complication, Critically Ill
Interventions
Fentanyl, Dexmedetomidine
Drug
Lead sponsor
Duke University
Other
Eligibility
Up to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
19
States / cities
Little Rock, Arkansas • Gainesville, Florida • Indianapolis, Indiana + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 15, 2026, 10:48 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial of Simvastatin to Treat Generalized Vitiligo

NCT01517893
View directory record Official record
Conditions
Vitiligo
Interventions
Simvastatin, Placebo
Drug
Lead sponsor
John Harris
Other
Eligibility
18 Years to 64 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Sep 15, 2026, 10:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Varenicline and Nicotine Interactions in Humans (VA)

NCT00606892
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline, Placebo, IV Nic
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Sep 15, 2026, 10:48 AM EDT
Active, not recruiting Not applicable Interventional

ViDES Trial (Vitamin D Extra Supplementation)

NCT05459298
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
Placebo, 800 IU/day vitamin D supplementation with feedings in the first 28 days after birth, Usual Care
Dietary Supplement · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
24 Hours to 96 Hours
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 15, 2026, 10:48 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers

NCT04618263
View directory record Official record
Conditions
Major Depressive Disorder, Excessive Sleepiness
Interventions
GATE-101
Drug
Lead sponsor
Syndeio Biosciences, Inc
Industry
Eligibility
18 Years to 40 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Sep 15, 2026, 10:48 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy

NCT05737784
View directory record Official record
Conditions
SCN2A-DEE, Epilepsy
Interventions
PRAX-222 - Initial Dose, PRAX-222 - Initial Ascending Doses, PRAX-222 - Optional Ascending Doses, PRAX-222 - Fixed Doses, Placebo
Drug · Procedure
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
2 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 15, 2026, 10:48 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of PATAS Trifluoroacetate Using Single Ascending Doses in Healthy Volunteers

NCT07223333
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
PATAS Trifluoroacetate, Placebo
Drug
Lead sponsor
AdipoPharma LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 15, 2026, 10:48 AM EDT